Cancer Treatment and the Ovary : (Record no. 54678)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06525nam a22004693i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC2111105 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729123830.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2015 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780128016015 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9780128015919 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC2111105 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL2111105 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11082366 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaONFJC)MIL822640 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)915311709 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC280.O8 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99/4 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Anderson, Richard A. |
| 245 10 - TITLE STATEMENT | |
| Title | Cancer Treatment and the Ovary : |
| Remainder of title | Clinical and Laboratory Analysis of Ovarian Toxicity. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | San Diego : |
| Name of producer, publisher, distributor, manufacturer | Elsevier Science & Technology, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2015. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2016. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (164 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Front Cover -- Cancer Treatment and the Ovary -- Copyright Page -- Contents -- List of Contributors -- Foreword -- Introduction -- I. Clinical -- 1 Ovarian Follicle Biology and the Basis for Gonadotoxicity -- 1.1 Overview of Ovarian Function -- 1.2 Ovarian Development -- 1.3 Molecular Mechanisms Controlling Primordial Follicle Activation -- 1.4 Local Control of Early Follicle Development -- 1.5 Endocrine Control of Later Follicle Development -- 1.6 Reproductive Lifespan and the Ovarian Primordial Follicle Reserve -- 1.7 Germ Cell Sensitivity to Cell Death -- 1.8 Conclusion -- References -- 2 Relevant Cancer Diagnoses, Commonly Used Chemotherapy Agents and Their Biochemical Mechanisms of Action -- 2.1 Introduction -- 2.2 Impact of Radiotherapy on Future Female Fertility -- 2.3 Impact of Chemotherapy on Future Female Fertility -- 2.4 Mechanisms of Action of the Commonly Used Chemotherapy Drugs -- 2.4.1 Alkylating Agents -- 2.4.2 Antimetabolites -- 2.4.3 Antitumour Antibiotics -- 2.4.4 Mitotic Inhibitors -- 2.4.5 Platinum Drugs -- 2.4.6 Topoisomerase Inhibitors -- 2.4.7 High-Dose Chemotherapy -- 2.4.8 Targeted Therapies -- References -- 3 Clinical Assessment of Ovarian Toxicity -- 3.1 Introduction -- 3.2 The Use of Chemotherapy-Related Amenorrhoea -- 3.3 Biomarkers of the Ovarian Reserve -- 3.4 AMH and Determination of Gonadotoxicity -- 3.4.1 After Chemotherapy -- 3.4.2 Prospective Analyses -- 3.4.3 Measurement of AMH -- 3.4.4 AMH in Paediatric Oncology -- 3.4.5 AMH and Prediction of Reproductive Lifespan and Fertility -- 3.5 Conclusion -- Acknowledgement -- References -- 4 The Current Understanding of Clinical Data on Ovarian Toxicity from Cancer Treatment -- 4.1 Introduction -- 4.2 Risk Factors for Premature Ovarian Insufficiency After Chemotherapy -- 4.2.1 Age -- 4.2.2 Type of Chemotherapy -- 4.2.3 Combined Treatment Protocols. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 4.2.3.1 Breast Cancer -- 4.2.3.2 Hodgkin Lymphoma -- 4.2.3.3 Non-Hodgkin Lymphoma -- 4.2.3.4 Leukaemia -- 4.2.3.5 Role of Gonadotropin-Releasing Hormone Analogues for the Preservation of Ovarian Function -- 4.3 How do Chemotherapeutics Damage The Ovary? -- 4.4 The Relevance of BRCA Mutations to Ovarian Damage After Chemotherapy -- 4.5 Conclusion -- References -- II. Laboratory Models -- 5 In Vivo Models of Ovarian Toxicity -- 5.1 Introduction -- 5.2 Rodent Models of Chemotherapy-Induced Follicular Depletion and Ovoprotection -- 5.2.1 Chemotherapy-Induced Follicular Depletion -- 5.2.2 Cell-Type Specificity of Chemotherapy Toxicity -- 5.2.3 Ovarian Toxicity Lessons from Ovoprotection Studies -- 5.2.4 Rodent Studies of Ovarian Chemotherapy Toxicity Compared to Data from Clinical Studies -- 5.2.5 Transgenerational Toxicity of Chemotherapy -- 5.3 Primate Models of Chemotherapy-Induced Ovarian Toxicity and Ovoprotection -- 5.4 Conclusion -- References -- 6 In Vitro Models of Ovarian Toxicity -- 6.1 Introduction -- 6.2 Why Use Culture Systems? -- 6.3 What Culture Systems are Available? -- 6.4 Human and other Primate Model Studies of Ovarian Chemotherapy Toxicity -- 6.5 Rodent Model Studies of Ovarian Chemotherapy Toxicity -- 6.6 Ovarian Cell Culture Techniques in Chemotherapy Studies -- 6.7 Conclusion -- References -- III. Strategies to Protect the Ovary -- 7 Ovarian Tissue Cryopreservation for Fertility Preservation -- 7.1 Overview -- 7.2 Ovarian Tissue Cryopreservation -- 7.3 Transplantation of Cryopreserved Ovarian Tissue -- 7.4 Outcome of Transplantations -- 7.5 Longevity of Grafts -- 7.6 Risk of Re-Implanting Malignant Cells -- 7.7 Conclusion -- References -- 8 Current Clinical Approaches to Protecting the Ovary: GnRH Analogues -- 8.1 Introduction -- 8.2 Distribution and Roles of the GnRH/GnRH Receptor System -- 8.2.1 GnRH -- 8.2.2 GnRH Receptor. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 8.2.3 GnRH and GnRHR Expression in the Ovary -- 8.2.4 Direct Effect of GnRH in the Ovary -- 8.3 GnRH Agonists -- 8.4 GnRH Agonist Co-treatment with Chemotherapy for the Protection of the Ovary -- 8.4.1 Animal Studies -- 8.4.2 Early Non-Randomized Studies in Human -- 8.4.3 Randomized Clinical Trials in Women -- 8.4.4 Meta-Analysis -- 8.5 Suggested Mechanisms of Gonadotoxic Protection by GnRH Agonists -- 8.6 Conclusion -- References -- 9 Preclinical Approaches to the Protection of Ovarian Function -- 9.1 Introduction -- 9.2 Ovarian Protection by Affecting Apoptotic Pathways -- 9.2.1 Imatinib -- 9.2.2 Sphingosine-1-Phosphate -- 9.2.3 Granulocyte Colony-Stimulating Factor -- 9.2.4 Thyroid Hormone (T3) -- 9.2.5 Tamoxifen -- 9.3 PI3K Follicle Activation Pathway and Ovary Protection -- 9.3.1 AS101 -- 9.4 Other Potential Methods of Reducing Chemotherapy-Induced Ovotoxicity -- 9.4.1 Interference with Transport: Bortezomib -- 9.4.2 Upregulation of Multidrug Resistance Gene (MDR1) -- 9.4.3 Drug Encapsulation -- 9.5 Conclusion -- References. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Ovaries -- Cancer -- Diagnosis. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Spears, Norah. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Anderson, Richard A. |
| Title | Cancer Treatment and the Ovary |
| Place, publisher, and date of publication | San Diego : Elsevier Science & Technology,c2015 |
| International Standard Book Number | 9780128015919 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=2111105">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=2111105</a> |
| Public note | Click to View |
No items available.